ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine months (Q3) 2024 in the morning of Thursday 14 November 2024.

Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and outlook and be available for questions.

ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.

Live audio webcast

The meeting will be audio webcasted live and be available for replay on ALK’s website

Conference call

If you wish to participate via telephone, please register for the conference call by using this link: and follow the instructions. You will receive an email from with dial-in details, including a passcode and a pin code. Please make sure to whitelist  and/or check your spam filter. We advise you to register on the day before the call at the latest.

Presentation

The presentation slides will be available on shortly before the meeting starts.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
07/11/2024

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Morten Larsen
  • Peter Sehested
8h / 44m 8h / 44m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Positive resultater fører peanut-tablet videre til fase II-udvikling

Positive resultater fører peanut-tablet videre til fase II-udvikling ALKs peanut-tablet påvist at være sikker og veltolereret på tværs af flere forskellige doserUdviklingen går nu ind i fase II, hvor dosisvalg og effekt undersøgesDe første patienter i fase II vil snart modtage deres første doser. Studiet ventes afsluttet i 2026. ALK (ALKB:DC / OMX: ALK B) har i dag annonceret positive interim-resultater fra det kliniske fase I/II studie (navngivet 'ALLIANCE') med sin sublinguale tabletvaccine ('SLIT') til behandling af peanutallergi. Denne del af studiet, som involverede cirka 30 patiente...

10h / 54m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Positive results advance peanut tablet to phase II development

Positive results advance peanut tablet to phase II development ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses imminently. Trial expected to complete in 2026. ALK (ALKB:DC / OMX: ALK B) today announced positive interim results from its phase I/II clinical trial (named ‘ALLIANCE’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy. This part of the trial, which involved approximately 30 patients, inv...

10h / 54m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ACARIZAX® godkendt i Europa til behandling af yngre børn

ACARIZAX® godkendt i Europa til behandling af yngre børn ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn i alderen fem til 11 år er blevet godkendt af sundhedsmyndighederne i 21 EU-lande via en type II variationsprocedure. De første lanceringer, blandt andet på ALK's største marked, Tyskland, forventes at finde sted over de kommende måneder.  Godkendelsen er baseret på data fra det største pædiatriske fase 3 AIT-studie (MT-12) med 1.458 børn i Nordamerika og Europa. MT-12-studiet...

December 12, 2024 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ACARIZAX® approved in Europe for treatment of young children

ACARIZAX® approved in Europe for treatment of young children ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure. The first market introductions, including in ALK’s largest market, Germany, are expected to follow over the coming months. The data that formed the basis for the approval includes results from the largest-ever paediatric AIT Phase 3 clinical trial, MT-...

December 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch